Shire Wins Baxalta With Revised $32 Billion Bid, Adding Cash

  • Baxalta holders to get $18 in cash, 0.1482 of Shire's ADRs
  • Shire expects to cut more than $500 million a year in costs

Inside Shire's Deal to Buy Baxalta for $32B

Shire Plc won over Baxalta Inc. by adding cash to sweeten a takeover bid worth about $32 billion and become the world’s biggest maker of drugs for rare diseases.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.